by Truveta staff | Mar 22, 2023 | News
Today, Truveta and Alpine Immune Sciences, Inc. announced a strategic partnership to help accelerate clinical trial recruitment for povetacicept, Alpine’s dual B cell cytokine antagonist being developed for multiple B cell-mediated autoimmune and inflammatory...
by Terry Myerson, CEO | Mar 1, 2023 | News
Today we are excited to announce that we’ve expanded the de-identified data in Truveta Studio to include 28 additional social drivers of health (SDOH) attributes – such as education, income, housing stability, social support, and more – for nearly 80 million...
by Truveta staff | Jan 10, 2023 | Technology
The key to any disease study is rich data. We recently met with the CEO of a biotech company that specializes in the development of immunotherapies. He and his team had tried to recruit patients for a series of clinical trials related to several rare disease...
